



## **Seal Rock Therapeutics Receives Grant from U.S. Army Medical Research Acquisition Activity to Support ALS Research Program**

**Seattle, WA, March 9, 2023** – Seal Rock Therapeutics, Inc., a clinical stage company developing first-in-class and best-in-class kinase inhibitors, today announced it has been awarded a \$547,000 grant from the U.S. Army Medical Research Acquisition Activity (USAMRAA) to support preclinical evaluation of Seal Rock’s LRRK2/ASK1 dual kinase inhibitor, SRT-055, as a potential development candidate for amyotrophic lateral sclerosis (ALS).

“We are pleased to receive this support from the USAMRAA that will allow us to explore the potential of SRT-055 for ALS.” said Neil McDonnell, CEO of Seal Rock. “This includes conducting proof-of-concept studies in ALS-relevant models, advanced characterization of SRT-055, pharmacokinetic and pharmacodynamic assessments as well as preclinical efficacy studies. We look forward to advancing these studies this year.”

This work is supported by The Assistant Secretary of Defense for Health Affairs and by the Department of Defense, in the amount of \$547,000.00, through the Amyotrophic Lateral Sclerosis Research Program Therapeutic Idea Award under Award No. W81XWH-22-ALSRP-TIA . Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the Department of Defense.”

### **About Seal Rock Therapeutics**

Seal Rock Therapeutics is a privately held, clinical stage company based in Seattle focused on developing first-in-class and best-in-class treatments for severe diseases with limited or no available therapies. Seal Rock is led by an experienced management team with a track record of successful drug discovery, development and commercialization. The company’s clinical-stage lead product candidate, SRT-015, is a highly optimized, first-in-class ASK1 inhibitor. Seal Rock is also developing preclinical-stage brain-penetrant ASK1/LRRK2 dual kinase inhibitors for treatment of neurodegenerative conditions such as Parkinson’s disease and ALS.

For more information, please visit [www.sealrocktx.com](http://www.sealrocktx.com)

###

**Media Contact:**

Julie Rathbun  
Rathbun Communications  
[Julie@rathbuncomm.com](mailto:Julie@rathbuncomm.com)  
206-769-9219